Newbridge Financial Services Group Inc. Buys Shares of 2,000 Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Newbridge Financial Services Group Inc. purchased a new position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) during the fourth quarter, HoldingsChannel.com reports. The fund purchased 2,000 shares of the specialty pharmaceutical company’s stock, valued at approximately $72,000.

Other large investors also recently modified their holdings of the company. GAMMA Investing LLC raised its stake in Supernus Pharmaceuticals by 97.1% during the third quarter. GAMMA Investing LLC now owns 808 shares of the specialty pharmaceutical company’s stock worth $25,000 after acquiring an additional 398 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Supernus Pharmaceuticals by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,993 shares of the specialty pharmaceutical company’s stock valued at $61,000 after purchasing an additional 352 shares during the last quarter. KBC Group NV raised its position in shares of Supernus Pharmaceuticals by 53.1% during the 4th quarter. KBC Group NV now owns 2,679 shares of the specialty pharmaceutical company’s stock worth $97,000 after purchasing an additional 929 shares during the period. Kennebec Savings Bank bought a new stake in shares of Supernus Pharmaceuticals in the 3rd quarter worth approximately $103,000. Finally, Janney Montgomery Scott LLC acquired a new position in Supernus Pharmaceuticals during the 4th quarter valued at approximately $211,000.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on SUPN shares. Cantor Fitzgerald started coverage on Supernus Pharmaceuticals in a research report on Monday, January 6th. They issued an “overweight” rating and a $57.00 target price on the stock. Cowen reaffirmed a “buy” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th. Finally, Piper Sandler reissued a “neutral” rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th.

Supernus Pharmaceuticals Price Performance

Shares of Supernus Pharmaceuticals stock opened at $37.93 on Tuesday. Supernus Pharmaceuticals, Inc. has a 1-year low of $25.53 and a 1-year high of $40.28. The business’s fifty day moving average price is $37.38 and its two-hundred day moving average price is $34.90. The company has a market capitalization of $2.09 billion, a P/E ratio of 35.45 and a beta of 0.90.

Insider Activity

In other news, VP Padmanabh P. Bhatt sold 700 shares of the stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $39.62, for a total value of $27,734.00. Following the completion of the transaction, the vice president now directly owns 10,149 shares in the company, valued at $402,103.38. This trade represents a 6.45 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 9.30% of the company’s stock.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.